Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0537-1482 Single Ascending Dose Study in Healthy Participants
NCT06625307Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0537-1482 in heart failure (HF) (7 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events at Day 15. Started Oct 2024; status: completed.
02
Drugs
NNC0537-1482
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06625307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625307.